Sponsor hub
Incyte Corporation clinical trial failures
Review 73 stopped clinical trials from Incyte Corporation, including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 10 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OPERATIONAL
- 42
- OTHER/UNKNOWN
- 21
- EFFICACY/FUTILITY
- 9
- SAFETY
- 1
Notable sponsors
- Incyte Corporation
- 73
Related phases
- Phase I
- 33
- Phase II
- 25
- Phase III
- 14
- Phase IV
- 1
Crawlable stopped-trial records
Open ExploreShowing up to 73 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase II Myelofibrosis trial by Incyte Corporation. Stop reason: OPERATIONAL.
The decision to close the study was made due to the expiration of remaining drug supply.
Phase I Advanced Solid Tumors trial by Incyte Corporation. Stop reason: OPERATIONAL.
This was a strategic business decision. There were no safety concerns contributing to this decision.
Phase II NSCLC (Non-small Cell Lung Carcinoma) trial by Incyte Corporation. Stop reason: OPERATIONAL.
Sponsor decision to not initiate part 2 due to slow enrollment and competing trials.
Phase I Melanoma trial by Incyte Corporation. Stop reason: OPERATIONAL.
Further development of this compound with ipilimumab in the treatment of melanoma is no longer being pursued.
Phase I NSCLC (Non-small Cell Lung Carcinoma) trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.
Phase I Chronic Lymphocytic Leukemia trial by Incyte Corporation. Stop reason: OPERATIONAL.
A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
Phase II Glioblastoma trial by Incyte Corporation. Stop reason: EFFICACY/FUTILITY.
Recruitment ceased after a pre-planned futility interim analysis indicated a low probability to confer a clinically meaningful improvement in objective response when compared to currently available therapies. There were no safety related concerns.
Phase IV Atopic Dermatitis trial by Incyte Corporation. Stop reason: OPERATIONAL.
The study was terminated due to lack of enrollment.
Phase II Metastatic Urothelial Carcinoma trial by Incyte Corporation. Stop reason: OPERATIONAL.
The reason this study was terminated was due to a business decision. There were no safety concerns that contributed to this decision.
Phase II Solid Tumor Malignancy trial by Incyte Corporation. Stop reason: OPERATIONAL.
A business decision was made to to discontinue further enrollment. There were no safety concerns that contributed to this decision.
Phase I Relapsed or Refractory Multiple Myeloma trial by Incyte Corporation. Stop reason: OPERATIONAL.
This decision follows recruitment difficulties. No safety-related concerns impacted this decision.
Phase I Solid Tumors and Hematologic Malignancy trial by Incyte Corporation. Stop reason: OPERATIONAL.
Strategic Business Decision
Phase I Acute Graft-versus-host Disease trial by Incyte Corporation. Stop reason: EFFICACY/FUTILITY.
The study was terminated due to insufficient efficacy in a separate phase III study
Phase III Warm Autoimmune Hemolytic Anemia (wAIHA) trial by Incyte Corporation. Stop reason: OPERATIONAL.
A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
Phase II Urothelial Carcinoma trial by Incyte Corporation. Stop reason: OPERATIONAL.
Business Decision. No safety concerns contributed to this decision.
Phase I Healthy Participants trial by Incyte Corporation. Stop reason: OPERATIONAL.
Strategic Business Decision
Phase II Myeloproliferative Neoplasm (MPN) trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
Termination of the clinical trial by sponsor.
Phase I Myelodysplastic Syndromes trial by Incyte Corporation. Stop reason: OPERATIONAL.
Strategic Business Decision
Phase III Myelofibrosis trial by Incyte Corporation. Stop reason: EFFICACY/FUTILITY.
The study was terminated due to futility.
Phase I Hematologic Malignancies trial by Incyte Corporation. Stop reason: OPERATIONAL.
Study terminated by sponsor
Phase I Solid Tumors trial by Incyte Corporation. Stop reason: OPERATIONAL.
Study terminated by Sponsor
Phase I Solid Tumors trial by Incyte Corporation. Stop reason: SAFETY.
Study terminated due to safety issues.
Phase I Hepatocellular Carcinoma (HCC) trial by Incyte Corporation. Stop reason: OPERATIONAL.
Strategic Business Decision
Phase I Relapsed Ewing Sarcoma trial by Incyte Corporation. Stop reason: OPERATIONAL.
Strategic Business Decision
Phase I Bronchiolitis Obliterans Syndrome trial by Incyte Corporation. Stop reason: OPERATIONAL.
Business Decision
Phase II Chronic Graft-versus-host Disease trial by Incyte Corporation. Stop reason: EFFICACY/FUTILITY.
The study was terminated due to insufficient efficacy to support moving into Part 2 of the study; there were no safety concerns that contributed to this decision.
Phase I Advanced Solid Tumors trial by Incyte Corporation. Stop reason: OPERATIONAL.
A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
Phase I Advanced Solid Tumors trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
The study was terminated after careful review of the overall clinical activity of this compound and a lack of robust efficacy. The study closure is not based on safety concerns.
Phase III Myelofibrosis trial by Incyte Corporation. Stop reason: EFFICACY/FUTILITY.
The study was terminated due to futility.
Phase I Advanced Solid Tumors trial by Incyte Corporation. Stop reason: OPERATIONAL.
This was a strategic business decision. There were no safety concerns contributing to this decision.
Phase III Unresectable Cholangiocarcinoma trial by Incyte Corporation. Stop reason: OPERATIONAL.
The study was terminated due to lack of enrollment resulting from a change in the standard of care for the first-line treatment of patients with cholangiocarcinoma. There were no safety concerns that contributed to this decision.
Phase I Advanced Solid Tumors trial by Incyte Corporation. Stop reason: OPERATIONAL.
This was a strategic business decision. There were no safety concerns contributing to this decision.
Phase II Non Small Cell Lung Cancer trial by Incyte Corporation. Stop reason: OPERATIONAL.
Strategic business decision to terminate the study effective immediately. This is due to a company decision to prioritize another oral PD-L1 inhibitor with a more favorable profile.
Phase I Melanoma trial by Incyte Corporation. Stop reason: OPERATIONAL.
This was a strategic business decision. There were no safety concerns contributing to this decision.
Phase II Advanced Malignancies trial by Incyte Corporation. Stop reason: OPERATIONAL.
A business decision due to availability of commercial drug and other options for accessing study drug treatment.
Phase II MPN (Myeloproliferative Neoplasms) trial by Incyte Corporation. Stop reason: OPERATIONAL.
A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
Phase I Lung Cancer trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Hand Eczema trial by Incyte Corporation. Stop reason: OPERATIONAL.
Business decision; no safety concerns.
Phase III Chronic Hand Eczema (CHE) trial by Incyte Corporation. Stop reason: OPERATIONAL.
Business decision; no safety concerns
Phase III Follicular Lymphoma ( FL) trial by Incyte Corporation. Stop reason: OPERATIONAL.
This study was withdrawn due to a business decision.
Phase II Advanced or Metastatic Solid Tumors trial by Incyte Corporation. Stop reason: OPERATIONAL.
The study was closed due to lack of enrollment.
Phase III Mantle Cell Lymphoma trial by Incyte Corporation. Stop reason: OPERATIONAL.
business decision; no enrolled patients
Phase I Solid Tumors trial by Incyte Corporation. Stop reason: OPERATIONAL.
A business decision made by Incyte after analysis of data from a sister study.
Phase III COVID-19 trial by Incyte Corporation. Stop reason: OPERATIONAL.
Study terminated by sponsor
Phase I Solid Tumors trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II MPN (Myeloproliferative Neoplasms) trial by Incyte Corporation. Stop reason: OPERATIONAL.
Enrollment issues
Phase II Alopecia Areata trial by Incyte Corporation. Stop reason: EFFICACY/FUTILITY.
The study was terminated early based on the results of a planned interim analysis.
Phase III Non-small Cell Lung Cancer trial by Incyte Corporation. Stop reason: OPERATIONAL.
Sponsor Strategic/Business Decision
Phase I Solid Tumors trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
Study was terminated early based on emerging data with epacadostat and pembrolizumab.
Phase I Advanced and/or Metastatic Solid Tumors trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
As of November 4, 2019 the study was halted prematurely and will not resume.
Phase I Solid Tumors trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Head and Neck Cancer trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
Study was cancelled prior to enrolling any patients.
Phase II Moderate to Severe Ulcerative Colitis trial by Incyte Corporation. Stop reason: OPERATIONAL.
Study withdrawn due to lack of recruitment. No patients enrolled. No safety concerns.
Phase I Sickle Cell Disease trial by Incyte Corporation. Stop reason: OPERATIONAL.
This study is terminated due to a business decision not to pursue INCB059782 in Sickle Cell Disease indication.
Phase I Solid Tumors trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Pemphigus Vulgaris trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
The study was withdrawn due to insufficient interest in study participation due to recent approval in this rare condition.
Phase I Solid Tumors and Hematologic Malignancy trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
As of 31 JAN 2018, the study was terminated by the sponsor due to PK variability.
Phase III Lung Cancer trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.
Phase III Pancreatic Cancer trial by Incyte Corporation. Stop reason: EFFICACY/FUTILITY.
The study was terminated early based on the results of the planned interim analysis.
Phase II Ovarian Cancer trial by Incyte Corporation. Stop reason: OPERATIONAL.
Study was terminated by the sponsor for lack of evidence of superiority and slow study accrual.
Phase II Solid Tumors and Hematologic Malignancy trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
Study withdrawn before enrolling first patient
Phase II HIV Infections trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
Development program ended due to inability to pair with other cytidine analogs and higher risk of hyperlipasemia when not used with 3TC/FTC.
Phase III Pancreatic Cancer trial by Incyte Corporation. Stop reason: EFFICACY/FUTILITY.
The safety committee found no safety issues but recommended halting the study based on a lack of efficacy in a similar trial. The sponsor terminated the trial.
Phase II Breast Cancer trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.
Phase II CRC (Colorectal Cancer) trial by Incyte Corporation. Stop reason: EFFICACY/FUTILITY.
Substudy 1 was terminated for futility at interim analysis and Substudy 2 was terminated per sponsor decision.
Phase II NSCLC (Non-small Cell Lung Carcinoma) trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.
Phase I Solid Tumors trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
Dose escalation ended after Cohort B1, RUX 10 mg BID - GCSF in October 2014.
Phase II Prostate Cancer trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
According to the protocol, the sponsor terminated the study after it was determined that less than 2 of the first 22 patients showed a PSA50 response.
Phase I Breast Cancer trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
Incyte suspended development of the compound.
Phase I MDS (Myelodysplastic Syndrome) trial by Incyte Corporation. Stop reason: OPERATIONAL.
Business decision.
Phase I Solid Tumor trial by Incyte Corporation. Stop reason: OPERATIONAL.
Business decision.
Phase II Refractory Hodgkin Lymphoma trial by Incyte Corporation. Stop reason: OTHER/UNKNOWN.
A decision was made to terminate the study due to the changing treatment landscape for the development of new agents in combination in Hodgkin lymphoma.
Phase II Rheumatoid Arthritis trial by Incyte Corporation. Stop reason: OPERATIONAL.
Business decision.